welcome
Home

Home

Health

Health

MindMed doses first subject in Phase III Panorama study of GAD tablet

Home
Summary
Nutrition label

86% Informative

MindMed has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT) The 52-week trial will take place across Europe and the US , aiming to enrol approximately 250 subjects.

VR Score

87

Informative language

85

Neutral language

82

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

Source diversity

1

Affiliate links

no affiliate links